• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Alpha Tau Medical Ltd.

    3/9/26 5:01:21 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email
    S-8 1 ea0280377-s8_alphatau.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 9, 2026

    Registration No. 333-              

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

     

     

    ALPHA TAU MEDICAL LTD. 

    (Exact name of Registrant as specified in its charter)

     

     

     

    State of Israel   Not applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    Kiryat HaMada St. 5

    Jerusalem, Israel

      9777605
    (Address of Principal Executive Offices)   (Zip Code)

     

    Alpha Tau Medical Ltd. 2021 Share Incentive Plan

    Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan 

    (Full Title of the Plan)

     

    Alpha Tau Medical, Inc.

    1 Union Street 3rd Floor 

    Lawrence, MA 01840
    (833) 455-3278
     

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies to:

     

    Joshua G. Kiernan

    Latham & Watkins LLP

    1271 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 906-1200

     

    Shachar Hadar
    Matthew Rudolph

    Meitar | Law Offices

    16 Abba Hillel Silver Rd.

    Ramat Gan 52506, Israel

    Tel: (+972) (3) 610-3100

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐   Accelerated filer ☒
    Non-accelerated filer ☐   Smaller reporting company ☐
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Pursuant to General Instruction E of Form S-8, Alpha Tau Medical Ltd. (the “Registrant,” “we” or “our”) is filing this Registration Statement with the Securities and Exchange Commission (the “SEC”) to register (i) 3,520,289 additional ordinary shares, no par value (“Ordinary Shares”), of the Registrant reserved for issuance under the Alpha Tau Medical Ltd. 2021 Share Incentive Plan (the “2021 Plan”) resulting from an automatic annual increase as of January 1, 2026 and (ii) 880,097 additional Ordinary Shares reserved for issuance under the Alpha Tau Medical Ltd. 2021 Employee Share Purchase Plan (the “ESPP”) resulting from an automatic annual increase as of January 1, 2026. Registration Statements of the Registrant on Form S-8 relating to the 2021 Plan and ESPP are effective.

     

     

     

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT

    ON FORM S-8

     

    Except as set forth below, the contents of the Registration Statements on Form S-8 (File Nos. 333-264169, 333-270406, 333-277733 and 333-285745), filed with the Securities and Exchange Commission, relating to the 2021 Plan and the ESPP, are incorporated herein by reference.

     

    1

     

     

    Item 8. Exhibits.

     

    Incorporation by Reference  
    Exhibit No.   Description   Form   File No.   Exhibit No.   Filing Date   Filed /
    Furnished
    4.1   Amended and Restated Articles of Association of Alpha Tau Medical Ltd.   20-F   001-41316   1.1   March 9, 2023    
    4.2   Specimen Ordinary Share Certificate   F-4   333-258915   4.5   January 5, 2022    
    5.1   Opinion of Meitar | Law Offices.                   *
    23.1   Consent of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, independent registered accounting firm                   *
    23.2   Consent of Meitar | Law Offices (included in Exhibit 5.1).                   *
    24.1   Power of Attorney (included on the signature page of the Registration Statement).                   *
    99.1   2021 Share Incentive Plan of Alpha Tau Medical Ltd.   F-4   333-258915   10.8   December 1, 2021    
    99.2   2021 Employee Share Purchase Plan of Alpha Tau Medical   F-4   333-258915   10.9   December 1, 2021    
    107   Filing Fee Table                   *

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jerusalem, Israel, on March 9, 2026.

     

      ALPHA TAU MEDICAL LTD.
         
      By: /s/ Uzi Sofer
       

    Name: 

    Uzi Sofer

        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Uzi Sofer and Raphi Levy, and each of them, individually, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all capacities, in connection with this Registration Statement, including to sign in the name and on behalf of the undersigned, this Registration Statement and any and all amendments thereto, including post-effective amendments and registrations filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and desirable to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date  
               
    /s/ Uzi Sofer   Chief Executive Officer & Chairperson   March 9, 2026  
    Uzi Sofer   (Principal Executive Officer)      
               
    /s/ Raphi Levy   Chief Financial Officer   March 9, 2026  
    Raphi Levy   (Principal Financial Officer and Principal Accounting Officer)      
               
    /s/ Ruth Alon   Director   March 9, 2026  
    Ruth Alon          
               
    /s/ Michael Avruch   Director   March 9, 2026  
    Michael Avruch          
               
    /s/ S. Morry Blumenfeld, Ph.D.   Director   March 9, 2026  
    S. Morry Blumenfeld, Ph.D.          
               
    /s/ Maya Netser   Director   March 9, 2026  
    Maya Netser          
               
    /s/ Alan Adler   Director   March 9, 2026  
    Alan Adler          
               
    /s/ David Milch   Director   March 9, 2026  

    David Milch

     

             
    /s/ Nadav Kidron   Director   March 9, 2026  
    Nadav Kidron          

     

    3

     

     

    AUTHORIZED REPRESENTATIVE

     

    Pursuant to the requirements of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Alpha Tau Medical Ltd. has signed this registration statement on Form S-8 on March 9, 2026.

     

      ALPHA TAU MEDICAL INC.
       
      By: /s/ Uzi Sofer
      Name: Uzi Sofer
      Title: President and Director

     

     

     

    4

     

     

    Get the next $DRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on Alpha Tau with a new price target

    Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

    12/15/23 8:07:49 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Alpha Tau with a new price target

    H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

    4/24/23 7:44:43 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    SEC Filings

    View All

    SEC Form S-8 filed by Alpha Tau Medical Ltd.

    S-8 - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 5:01:21 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by Alpha Tau Medical Ltd.

    20-F - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 4:03:11 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 4:03:17 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

    - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NE

    3/9/26 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

    - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan's Ministry of Health, Labour and Welfare ("MHLW") has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally

    2/24/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

    - Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for commercial readiness - Jerusalem, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today issued the following letter to shareholders: Dear Shareholders, Following an incredibly productive 2025, culminating in several significant announcements in recent weeks, I wish to sha

    1/29/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

    JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

    5/12/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    3/12/25 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

    JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

    12/17/24 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care